Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0478 • ACR Convergence 2025
Racial and Ethnic Disparities in DMARD Use and in Medicare Part B-Covered Options Among Medicare Beneficiaries with Late-Onset Rheumatoid Arthritis
ashkan ara¹, John FitzGerald² and Susan Ettner², ¹UCLA Health, Los Angeles, CA, ²UCLA, Los Angeles, CA
Background/Purpose: Biologic and targeted synthetic DMARDs can substantially improve the quality of life for Medicare beneficiaries with rheumatoid arthritis (RA). However, racial and ethnic disparities…
Abstract Number: 0462 • ACR Convergence 2025
Does Biological Sex Affect Mortality in Frail Patients with Rheumatoid Arthritis?
Sayuli Bhide¹, Hannah Brubeck², Punyasha Roul³, Aaron Baraff², Bryant England⁴, Nadine El-Ayache¹, Grant Cannon⁵, Namrata Singh⁶, Gary Kunkel⁷, Ted Mikuls⁴, Dolores Shoback⁸, Kaleb Michaud⁴, Patti Katz⁹, Jose Garcia¹⁰, Ariela Orkaby¹¹, Joshua Baker¹² and Katherine Wysham¹³, ¹University of Washington, Seattle, WA, ²VA Puget Sound Health Care System, Seattle, WA, ³UNMC, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁶University of Washington, Bellevue, WA, ⁷University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁸San Francisco VA Medical Center & University of California San Francisco, San Francisco, CA, ⁹UCSF, San Rafael, CA, ¹⁰VA Puget Sound Health Care System, VA GRECC, and University of Washington, Seattle, WA, ¹¹Veterans Affairs Boston Healthcare System & Brigham and Women’s Hospital, Boston, MA, ¹²University of Pennsylvania, Philadelphia, PA, ¹³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA
Background/Purpose: Frailty predicts mortality in RA. In the general population, males have a higher risk of death than females despite lower levels of frailty.1 We…
Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Giorgos Loizidis and Ross summer, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…
Abstract Number: 0379 • ACR Convergence 2025
Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study
Rosa Maria Morlà Novell¹, Enrique González-Dávila², Beatriz Frade Sosa³, Maria López-Lasanta⁴, Noemí Busquets Pérez⁵, Marta Valls Roc⁶, Meritxell Sallés Lizarzáburu⁷, Georgina Salvador Alarcón⁸, Virginia Ruiz-Esquide⁹, Lola Tobalina Mastre¹⁰, José Gomez-Puerta¹¹ and Raimon Sanmartí⁹, ¹Hospital Clínic de Barcelona, Barcelona, Spain, ²Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, ³Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, ⁴Hospital Universitari Vall d´Hebron, Barcelona, Spain, ⁵Hospital de Granollers, Granollers, Spain, ⁶Hospital Universitari Dr Trueta, Girona, Sudan, ⁷Xarxa Sanitària Althaia Manresa, Manresa, Spain, ⁸Hospital Universitari Mùtua Terrassa, Terrassa, Spain, ⁹Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹⁰IDIBAPS. Hospital Clinic de Barcelona, Barcelona, ¹¹Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
Abstract Number: 0215 • ACR Convergence 2025
Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients
Alexandra Kobza¹, Camille Bourgeois², Olivier Fogel³, Maxime Dougados⁴ and Anna Molto⁵, ¹University of Calgary, North Vancouver, BC, Canada, ²Hospital general universitario Gregorio Marañon, Madrid, Madrid, Spain, ³AP-HP, Paris, France, ⁴Department of Medicine, Hopital Cochin, Universite de Paris, Paris, France, ⁵Assistance Publique Hôpitauxde Paris, Paris, France
Background/Purpose: Patients with inflammatory arthritis (IA), including rheumatoid arthritis (RA) and spondyloarthritis (SpA), face elevated risk for comorbidities that complicate disease management. Although rheumatology societies…
Abstract Number: 0147 • ACR Convergence 2025
Rheumatoid Arthritis prevalence estimation in France using care pathways in the National Health Data System: opportunities and limitations – PREST study
cécile gaujoux-viala¹, adeline Ruyssen-Witrand², Laurent arnaud³, clélia Bignon-Favary⁴, Lauren Inchboard⁴ and Bruno Fautrel⁵, ¹Department of Rheumatology - CHU Nîmes, IDESP UM¹³¹⁸  INSERM – Univ. Montpellier, Nîmes, France, Nîmes, France, ²Department of Rheumatology, C.H.U. de Toulouse, CIC ¹⁴³⁶, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, Toulouse, France, ³Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, INSERM UMR-S ¹¹⁰⁹, Strasbourg, France, Strasbourg, France, ⁴Horiana, Statistiques, Bordeaux, France, Bordeaux, France, ⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France
Background/Purpose: A total of 98.8% of French citizens are registered in the National Health Data System (SNDS), which includes claims data of all reimbursed health-related…
Abstract Number: 0083 • ACR Convergence 2025
Confirmatory Factor Analysis of the Plutchik Suicide Risk Scale in Patients with Rheumatoid Arthritis
Pedro Quevedo¹, Javier mora², william garcia², alejandra Solano², juliana Muñoz² and Daniela Lopez², ¹San Rafael Cinic University Hospital, Bogota, Distrito Capital de Bogota, Colombia, ²san rafael clinic universtity hospital, Bogota, Distrito Capital de Bogota, Colombia
Background/Purpose: Prevalence of depression in RA patients ranging from 10% to 25%, making it the most common psychiatric disorder in this population. The Plutchik Suicide…
Abstract Number: 0062 • ACR Convergence 2025
Neddylation as a Therapeutic Target in Autoimmune Arthritis: Evidence from SKG Mice
Sho Sendo¹, Alfonso Del Peral Fanjul², Kazuma Nishisaka², Hirotaka Yamada¹, Takaichi Okano¹, Keisuke Nishimura¹, Yo Ueda¹ and Jun Saegusa², ¹Kobe University Hospital, Kobe, Japan, ²Kobe University, Kobe, Japan
Background/Purpose: Neddylation, NEDD8 conjugating process, is a post-translational modification that plays a crucial role in regulating ubiquitination by targeting cullin (CUL)-ring E3 ubiquitin ligases. Our…
Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Koray Tascilar¹, Alp Temiz¹, Filippo Fagni², Arnd Kleyer³, Louis Schuster¹, Stephan Kemenes¹, Sara Bayat¹, David Simon⁴ and Georg Schett⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Charite Universitätsmedizin Berlin, Erlangen, Bayern, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁵Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…
Abstract Number: 2619 • ACR Convergence 2025
What Works? A Consolidated Framework for Implementation Research-Guided Exploration of Patient Safety in Rheumatology Practices
Catherine Nasrallah¹, Cherish Wilson², Christine Hariz³, Alicia Hamblin⁴, Cammie Young⁵, gabriela Schmajuk⁶ and Jinoos Yazdany⁴, ¹University of California San Francisco (UCSF), San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³University of California San Francisco (UCSF, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵University of California, San Francisco, Oakland, CA, ⁶University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA
Background/Purpose: Despite widespread recognition of persistent patient safety challenges in the U.S. health care system, the development of feasible and scalable solutions has lagged, particularly…
Abstract Number: 2287 • ACR Convergence 2025
Interpretable Ensemble Machine Learning Explaining Nonadherence and the Risk of Nonpersistence of Targeted Disease-Modifying Antirheumatic Agents in Older Adults with Rheumatoid Arthritis
yinan huang¹ and Sandeep Agarwal², ¹Department of Pharmacy Administration, University of Mississippi, Oxford, MS, US, MS, ²Baylor College of Medicine, Houston
Background/Purpose: Interpretable machine learning (ML) method can identify factors associated with biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) nonadherence and nonpersistence for rheumatoid…
Abstract Number: 2270 • ACR Convergence 2025
ACKR1 and Leukopenia in Patients with Rheumatoid Arthritis Treated with Disease Modifying Antirheumatic Drugs
Daniela Chavez de Paz Solis¹, Puran Nepa², Laura Daniel³, Yan Guo⁴, Jonathan Mosley⁵, Michael Stein⁶ and Cecilia Chung⁴, ¹University of Maine, Caribou, ME, ²University of Miami, Research Service, Miami VA Healthcare System, Miami, FL, ³University of Miami, Nashville, TN, ⁴University of Miami, Miami, ⁵UT Southwestern Medical Center, Dallas, ⁶Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) such as methotrexate, sulfasalazine, and leflunomide arecommonly prescribed for RA treatment but carry the risk of leukopenia. The ACKR1 promoter…
Abstract Number: 2254 • ACR Convergence 2025
Association of disease activity with insomnia, depression, and fatigue in patients with rheumatoid arthritis: a multicenter prospective observational study
Misako Higashida-Konishi¹, Keisuke Izumi², Shuntaro Saito Saito³, Hiroki Tabata⁴, Satoshi Hama⁴, Tatsuhiro Oshige⁴, Yutaka Okano⁴, Hisaji Oshima⁴, Katsuya Suzuki⁴, Jiro Sakamoto⁵, Toshikazu Fukami⁵, Kazumichi Minato⁵, Nobuhiko Kajio⁶, Yasushi Kondo³, Hiroaki Taguchi⁶ and Yuko Kaneko³, ¹NHO Tokyo Medical Center, Tokyo Meguroku, Japan, ²Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center/Keio University School of Medicine/TechDoctor, Inc., Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Medicine, NHO Tokyo Medical Center, Tokyo, Japan, ⁵TechDoctor, Inc., Tokyo, Japan, ⁶Department of Rheumatology, Kawasaki Municipal Hospital, Kanagawa, Japan
Background/Purpose: Patients with rheumatoid arthritis (RA) often experience not only joint-related symptoms but also systemic issues such as insomnia, depression, and fatigue [1–3]. These symptoms…
Abstract Number: 2237 • ACR Convergence 2025
Safety of DMARD therapy in veterans with rheumatoid arthritis following melanoma diagnosis: a survival analysis
Gabriella Girolami¹, Shamey Kassim², Alexander Peterson³, Aaron Baraff³, Alexandra Schmidt³, Shailender Bhatia⁴, Natalie Miller⁴, Jennifer Barton⁵, Jeffrey Curtis⁶, Christopher Li⁴ and Namrata Singh⁷, ¹University of Washington, Seattle, ²University of Washington, Seattle, WA, ³VA Puget Sound Health Care System, Seattle, WA, ⁴Fred Hutch Cancer Center, Seattle, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL, ⁷University of Washington, Bellevue, WA
Background/Purpose: While disease-modifying anti-rheumatic drugs (DMARDs) are critical in managing rheumatoid arthritis (RA), their immunosuppressive effects raise concerns about cancer-related outcomes. In patients with RA…
Abstract Number: 2176 • ACR Convergence 2025
Addressing Hesitancy in JAK Inhibitor Use: Outcomes from Continuing Medical Education Reveal Confidence-Knowledge Gaps Among Community Rheumatologists
Carole Drexel¹, Eve Wilson², Vibeke Strand³ and Jon Giles⁴, ¹Medlive, Pasadena, MD, ²Medlive, Needham, MA, ³Stanford University School of Medicine, Palo Alto CA, Portola Valley, CA, ⁴Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Despite supportive real-world evidence, the use of Janus kinase inhibitors (JAKi) for rheumatoid arthritis (RA) remains limited in community settings. Concerns stemming from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].